Liver-specific distribution of rosuvastatin in rats: Comparison with pravastatin and simvastatin

Drug Metabolism and Disposition

Volumn 30, Issue 11, 2002, Pages 1158-1163

  Nezasa, Ken Ichi ^a   Higaki, Kazutaka ^b   Matsumura, Tadahiko ^a   Inazawa, Kazuhiro ^a   Hasegawa, Hiroshi ^a   Nakano, Masayuki ^a   Koike, Masahiro ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; HYPOCHOLESTEROLEMIC AGENT; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG SELECTIVITY; DRUG UPTAKE; ISOTOPE LABELING; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN; TISSUE DISTRIBUTION; ALGORITHM; ANIMAL; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; METABOLISM; SILVER STAINING; SPRAGUE DAWLEY RAT;

ANIMALIA;

ALGORITHMS; ANIMALS; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; AUTORADIOGRAPHY; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; MALE; PRAVASTATIN; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SILVER STAINING; SIMVASTATIN; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 0036840329     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.11.1158     Document Type: Article

References (17)

1. Brown CDA, Windass A, Bleasby K, and Lauffart B (2001) Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C (abstract). Atheroscler Suppl 2:90.
2. Kim DC, Sugiyama Y, Satoh H, Fuwa T, Iga T, and Hanano M (1988) Kinetic analysis of the receptor dependent uptake of human epidermal growth factor by the tissues of the rat in vivo. J Pharm Sci 77:200-207.
3. Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, and Tsujita Y (1992) Tissue selectivity of pravastatin sodium. Iovastain and simvastatin. Eur J Biochem 209:315-319.
4. Koga T, Kikuchi T, Miyazaki A, and Koike H (1995) Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Lipids 30:775-779.
5. Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, and Horiuchi S (1992) Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 43:667-670.
6. Maron DJ, Fazio S, and Linton MF (2000) Current perspectives on statins. Circulation 101:207-213.
7. Matsuyama K, Nakagawa K, Nakai A, Konishi Y, Nishikata M, Tanaka H, and Uchida T (2002) Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol Pharm Bull 25:346-350.
8. McTaggart F, Buckett L, Davidson R, Holdgate G. McCormick A, Schneck D, Smith G, and Warwick M (2001) Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87 (Suppl):28B-32B.
9. Olsson AG, Pears J, McKellar J, Mizan J, and Raza A (2001) Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-8.
10. Paoletti R, Fahmy M, Mahla G, Mizan J, and Southworth H (2001) ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines (abstract). J Am Coll Cardiol 37 (Suppl A):291A.
11. Pierno S, De Luca A, Liantonio A, Camerino C, and Conte Carmerino D (1999) Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol 364:43-48.
12. Serajuddin ATM, Ranadive SA, and Mahoney EM (1991) Relative lipophilicities, solubilities and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin and simvastatin. J Pharm Sci 80:830-834.
13. van Vliet A, Van Thiel G, Huisman RH, Moshage H, Yap SH, and Cohen LH (1995) Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochem Biophys Acta 1254:105-111.
14. Watanabe M, Koike H, Ishida T, Okada T, Seo S, and Hirai K (1997) Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem 5:437-444.
15. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
16. Yamazaki M, Tokui T, Ishigami M, and Sugiyama Y (1996) Tissue-selective uptake of pravastatin in rats: Contribution of a specific carrier-mediated uptake system. Biopharm Drug Dispos 17:775-789.
17. Yanai S, Sugiyama Y, Iga T, Fuwa T, and Hanano M (1990) Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am J Physiol 258:C593-C598.